Actinium Pharmaceuticals, Inc. announced on October 15, 2026, that Dr. Matt David has been appointed as the company's Chief Financial Officer and principal financial officer. Dr. David, age 49, commenced service on October 14, 2026, following an offer letter signed on September 30, 2026.
According to the filing, Dr. David brings over 20 years of experience in life sciences, corporate finance, capital markets, and investor relations. His most recent role was as Chief Business Officer at CorMedix Inc., where he also served as Chief Financial Officer from May 2020 to September 2025. During his tenure at CorMedix, he oversaw finance and capital markets and supported the acquisition of Melinta Therapeutics in 2025. Previously, he held leadership roles at Ovid Therapeutics and worked in healthcare investment banking at firms including BofA Merrill Lynch, Piper Jaffray, and Thomas Weisel Partners.
The appointment is detailed in an 8-K filing, which outlines Dr. David's compensation and equity awards. Under the offer letter, he will receive an annual base salary of $450,000 and a target annual performance bonus of 40% of his base salary. Additionally, he is set to receive a $150,000 sign-on bonus and a guaranteed prorated target bonus for 2026, contingent on continued employment.
In connection with his appointment, Dr. David was granted an option to purchase 250,000 shares of the Company’s common stock and 325,000 restricted stock units (RSUs) under the 2026 Employment Inducement Award Plan. The option has an exercise price equal to the closing market price on the grant date and vests over four years. The RSUs include both time-based and performance-based vesting tied to corporate milestones.
The filing also notes that the Inducement Plan was adopted by the Board on September 2, 2026, without stockholder approval, in accordance with Section 711(a) of the NYSE American Company Guide. The Company also furnished a press release dated October 15, 2026, announcing the appointment.
